<DOC>
	<DOCNO>NCT00471549</DOCNO>
	<brief_summary>Diabetes associate dyslipidaemia lead generalized atherosclerosis , cardiovascular disease ( CVD ) nephropathy . Osteoprotegerin ( OPG ) , glycoprotein involved bone homeostasis , implicate pathogenesis lead vessel calcification . Furthermore , CVD diabetic associate increased level OPG . Aim : To investigate whether low dose simvastatin treatment ( 10-20 mg/day ) reduce circulate level OPG well adhesion molecule ( VCAM-1 ; vascular cell adhesion molecule-1 , ICAM ; intercellular cell adhesion molecule ) .</brief_summary>
	<brief_title>Simvastatin Reduces Circulating Osteoprotegerin Levels Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Type 2 diabetes associate increased risk macro- microvascular complication , result generalized injury vascular endothelium . The pathophysiological mechanism lead cardio vascular disease ( CVD ) diabetic well define . However , accumulate evidence , damage vascular smooth muscle cell endothelial cell partly occur vessel shear stress , change nitric oxide , increase cytokine level ( i.e . TNF-α : tumour necrosis factor-α IL-1 : interleukin-1 ) . This ultimately result sclerosis basal membrane cause endothelial cell proliferation increase vascular permeability , allow protein leak extra cellular matrix . Atherosclerotic lesion may also arise result accumulation monocyte macrophage contain oxidise LDL ( foam cell ) arterial wall . This process initiate expression adhesion molecule ( e.g . VCAM-1 ; vascular cell adhesion molecule-1 , ICAM ; intercellular cell adhesion molecule ) luminal surface vascular endothelial cell , allow cellular attachment migration vascular wall . Osteoprotegerin ( OPG ) , secrete basic glycoprotein member TNF receptor superfamily , soluble receptor activator nuclear factor-κB ( RANK ) ligand ( RANKL ) , TNF-related apoptosis induce ligand ( TRAIL ) , though much low affinity TRAIL compare RANKL . OPG work decoy-receptor prevent RANK-RANKL interaction , thereby reduce biological effect . The RANK-RANKL system induces osteoclast differentiation activation whereby bone absorption promote . Due property decoy receptor , OPG antagonize effect inhibits bone loss . In addition effect osteoclast , RANK-RANKL system propose cardiovascular effect . Thus , activation RANK-RANKL system induce VCAM-1 synthesis , prolongs endothelial cell survival , promote angiogenesis , reduce TNF-α level . In contrast , elevate level OPG associate severity CVD , although presently unclear whether association reflect cause-effect relationship purely coincidental . Cholesterol-lowering therapy statin reduces cardiovascular mortality morbidity risk diabetic non-diabetic subject . According recent study , statin may additional , pleiotropic effect may fact stabilize atherosclerotic plaque . Experimental data obtain animal model indicate dose-dependent angiogenetic effect promotion vascular structure formation . It therefore interest recent , vitro study Ben-Tahl et al . Rasmussen et al . suggest statin may suppress OPG adhesion molecule production human . Thus , umbilical vein endothelial cell smooth vascular muscle cell incubate simvastatin stimulate TNF-α IL-1 secrete less OPG control cell . Under normal circumstance , exposure cytokine ( TNF-α IL-1 ) powerful stimulus OPG production vascular cell result therefore seem support concept , simvastatin may ameliorate deleterious effect inflammation . This study conduct examine effect simvastatin treatment circulate OPG adhesion molecule level group type 2 diabetic patient increase risk cardiovascular disease ( CVD ) due persistent microalbuminuria . Since OPG adhesion molecule associate CVD potentially modifiable statin treatment could help improve understand potentially pleiotropic effect statins reduce CVD .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Type 2 diabetes Persistent microalbuminuria Fasting plasma cholesterol &gt; 5.5 mmol/liter Fasting plasma triglyceride &lt; 4.5 mmol/liter Fasting HbA1c &lt; 10 % Fasting serum Cpeptide &gt; 0.49 nmol/liter Blood pressure &lt; 155/95 Signs primary kidney disease Signs primary hepatic disease Signs insufficiently treat cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Dyslipidaemia</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Osteoprotegerin</keyword>
	<keyword>Adhesion molecule</keyword>
	<keyword>Simvastatin</keyword>
</DOC>